Preclinical Kidney Disease R&D Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Immune-Mediated Nephropathies Models

Inquiry

Immune-mediated nephropathies represent complex disorders driven by dysregulated immune responses, leading to renal inflammation and progressive dysfunction. At Ace Therapeutics, we specialize in preclinical research services utilizing rigorously validated disease models to support drug discovery and mechanistic investigations. Our platforms are designed to replicate key immunological pathways and renal injury patterns observed in human immune-mediated kidney diseases.

Importance of Immune-Mediated Nephropathies in Drug Discovery

Immune-mediated nephropathies encompass a spectrum of glomerular diseases driven by autoantibody formation, immune complex deposition or autoreactive T cell infiltration. Precise modeling of these conditions underpins:

Identification of target engagement windows and therapeutic mechanisms
Biomarker development for patient stratification and monitoring
Safety and efficacy profiling of biologics and small molecules

By recapitulating hallmark features such as proteinuria, complement activation and histological lesions, our models facilitate mechanistic studies and support preclinical candidate selection.

Disease Models Offered

We maintain an array of validated models to address diverse immune-mediated kidney pathologies:

Model name and acronym	Species/Strain	Key features
Anti-glomerular basement membrane (NTN)	C57BL/6 mouse, Wistar rat	Rapid onset proteinuria, crescent formation
Lupus nephritis	NZB/W F1 and MRL/lpr mice	Autoantibody-driven glomerulonephritis
IgA nephropathy	ddY mouse, gd-IgA1 challenge	Mesangial IgA deposition, hematuria
Passive Heymann nephritis (PHN)	Sprague–Dawley rat	Membranous injury, subepithelial deposits
ANCA-associated vasculitis	C57BL/6 mouse	Pauci-immune glomerulonephritis, necrosis

Custom and Emerging Models

Beyond these core systems, Ace Therapeutics can develop or adapt models such as cytokine-induced interstitial nephritis or transgenic systems expressing human autoantigens to mirror cutting-edge therapeutic targets.

Model Validation and Quality Control

Reproducibility and translational fidelity are ensured through standardized validation pipelines:

Validation Parameter	Methodology
Functional kidney assessment	Transdermal GFR monitoring, serum creatinine
Histological scoring	Semi-quantitative analysis of glomerular lesions
Immunohistochemistry	Staining for complement (C3, C5b-9) and CD3
Biomarker profiling	Urinary proteinuria, NGAL, KIM-1 panels
Molecular readouts	RT-qPCR for pro-inflammatory cytokines

Routine batch controls, blinded histopathology reads and inter-cohort comparisons safeguard data integrity and cross-study consistency.

Integrated Preclinical Platform

At Ace Therapeutics, each project benefits from a coordinated workflow that includes:

Collaborative project design and model selection based on your therapeutic goal
Customized induction protocols to generate consistent disease phenotypes
Multi-modal assessments including functional, histological and molecular endpoints
Comprehensive data packages delivering raw data, statistical analysis and expert interpretation
Dedicated scientific advisors guide every phase, ensuring methodological rigor and alignment with regulatory expectations for preclinical research.

Why Choose Us?

Flexible model customization targeting specific mechanisms or patient-relevant features
End-to-end project management with transparent communication and timelines
Multidisciplinary team of nephrology, immunology and pharmacology experts
Comprehensive raw data delivery accompanied by expert interpretation
Adherence to institutional animal care guidelines and ethical standards

Collaborating with Ace Therapeutics accelerates your preclinical program, reduces rework and enhances confidence in candidate selection.

Frequently Asked Questions (FAQs) About PKD Model

How do I select the most appropriate model for my compound?

Our scientific advisors review your target, mechanism and therapeutic modality to recommend models that best align with your study objective, whether that involves autoantibody blockade, complement inhibition or T cell modulation.

Can comorbidities be integrated into these immune-mediated models?

Yes. We can incorporate factors such as hypertension, diabetes or aging to reflect clinical complexity and evaluate compound performance under multifactorial stress.

What endpoints are typically measured?

Standard readouts include proteinuria, serum creatinine, histopathological scoring, complement deposition, cytokine panels and, where relevant, imaging biomarkers of renal structure and perfusion.

Do you offer PK/PD studies alongside nephropathy models?

We provide integrated pharmacokinetic assessments and link exposure metrics to efficacy endpoints, supporting informed dose selection for translational studies.

How do you ensure reproducibility across cohorts?

Quality control measures include standardized induction protocols, blinded pathology assessments, batch controls for reagents and regular inter-cohort comparisons to monitor consistency.